Andy Studna, Editor

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how regulatory bodies are currently viewing the data collection space.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how eCOAs are being applied to clinical trials.

With so many new solutions and other technologies appearing in the clinical trials space, how are stakeholders choosing which ones are best for them and how are these advancements translating to the actual clinic?

While clinical research in rare diseases has many unique operational challenges, there is plenty of work being done to advance it and bring effective therapies to patients.

Bingham discusses the logistical challenges associated with coordinating patient involvement in rare disease clinical trials.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, gives an overview of Vulcan at the 2023 DPHARM conference in Boston, MA.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, shares what she is currently seeing in the data space of clinical trials at the 2023 DPHARM conference in Boston, MA.

How can industry bring its latest technologies together?

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses what the future of patient recruitment could look like at the 2023 DPHARM conference in Boston, MA.

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses the challenges industry is currently seeing in patient recruitment at the 2023 DPHARM conference in Boston, MA.

ObjectiveHealth presents real-world case study on enrollment solutions in DPHARM 2023 session.

With the recent boom in artificial intelligence (AI), industry is finding ways to best utilize it in advancing the development of potential therapies.

New models such as IROs are changing the way industry views the current site landscape and addressing challenges.

Innovative pharma companies are stepping up to integrate digital health technology to advance pharmaceutical drug and medical device development, in both the healthcare and research worlds, to achieve better measurements and outcomes.

Raj Indupuri, CEO and co-founder of eClinical Solutions discusses the trends he is seeing with artificial intelligence in the clinical trials space.

The evolution of data and digital health uses in both the healthcare and research worlds is bringing the two closer together for the good of patients.

Integrated research organizations (IROs) are creating a shift in the way clinical trials are operated, bringing new methods for enrollment and building patient-physician relationships.

In this Q&A, Jimmy Bechtel, MBA, VP of site engagement, Society for Clinical Research Sites discusses evolving challenges in the site landscape, what SCRS is doing to alleviate burden, as well as the organization’s upcoming event, the Global Site Solutions Summit in October 2023.

From startups to major research organizations, early-phase research can be managed in different ways depending on the company.

DIA session focuses on the ins and outs of returning individual participant data.

DIA session highlights strategies for stakeholders to make clinical trials more inclusive for diverse populations.

Panel at DIA discussed the evolving role of pharmacies in clinical trials.

The many sources of data source in clinical trials can be overwhelming, but the data itself can be used positively to guide clinical operations decision-making.

Jennifer Duff, General Manager, Zelta Clinical Trials Solutions, Merative (formerly IBM Watson Health), discusses her leadership philosophy, major technological changes are impacting clinical trials operations professionals today and in the future, plus much more.

Harsha K. Rajasimha, PhD, founder and executive chairman, IndoUSrare, provides the OCT audience insights into better achieving DEIA clinical trials.

Senior leaders gather to share insights on the increased investment in real-world data to boost the quality and efficiency of drug development—as the industry begins to more widely embrace evidence of proven outcomes in aiding approaches in clinical trial design, patient engagement, regulatory decision-making, and other areas.

Doug Warner, MD and CMO for eFFECTOR Therapeutics, discusses the complexities of oncology clinical trials, the important relationship medical directors should have with their clinical study teams, and more.

Peter Benton, President and CO-CEO for Worldwide Clinical Trials, speaks about his unconventional entrance into the industry, advice for clinops professionals, and much more.

Sindhu Ramchandren, MD, Director, Clinical Leader, Neuroscience at Janssen, discusses the importance of having physicians involved in clinical trials, walks us through her career path and more.